Literature DB >> 31915130

Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.

Shipra Das1, Beny Shapiro1, Emily A Vucic1, Sandra Vogt1, Dafna Bar-Sagi2.   

Abstract

Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy typified by a highly stromal and weakly immunogenic tumor microenvironment that promotes tumor evolution and contributes to therapeutic resistance. Here, we demonstrate that PDA tumor cell-derived proinflammatory cytokine IL1β is essential for the establishment of the protumorigenic PDA microenvironment. Tumor cell-derived IL1β promoted the activation and secretory phenotype of quiescent pancreatic stellate cells and established an immunosuppressive milieu mediated by M2 macrophages, myeloid-derived suppressor cells, CD1dhiCD5+ regulatory B cells, and Th17 cells. Loss of tumor cell-derived IL1 signaling in tumor stroma enabled intratumoral infiltration and activation of CD8+ cytotoxic T cells, attenuated growth of pancreatic neoplasia, and conferred survival advantage to PDA-bearing mice. Accordingly, antibody-mediated neutralization of IL1β significantly enhanced the antitumor activity of α-PD-1 and was accompanied by increased tumor infiltration of CD8+ T cells. Tumor cell expression of IL1β in vivo was driven by microbial-dependent activation of toll-like receptor 4 (TLR4) signaling and subsequent engagement of the NLRP3 inflammasome. Collectively, these findings identify a hitherto unappreciated role for tumor cell-derived IL1β in orchestrating an immune-modulatory program that supports pancreatic tumorigenesis. SIGNIFICANCE: These findings identify a new modality for immune evasion in PDA that depends on IL1β production by tumor cells through TLR4-NLRP3 inflammasome activation. Targeting this axis might provide an effective PDA therapeutic strategy. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 31915130      PMCID: PMC7302116          DOI: 10.1158/0008-5472.CAN-19-2080

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Epidemiology of pancreatic adenocarcinoma.

Authors:  Priya K Simoes; Sara H Olson; Amethyst Saldia; Robert C Kurtz
Journal:  Chin Clin Oncol       Date:  2017-06

2.  CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.

Authors:  Timothy Chao; Emma E Furth; Robert H Vonderheide
Journal:  Cancer Immunol Res       Date:  2016-10-13       Impact factor: 11.151

Review 3.  Strategies for Increasing Pancreatic Tumor Immunogenicity.

Authors:  Burles A Johnson; Mark Yarchoan; Valerie Lee; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2017-04-01       Impact factor: 12.531

4.  Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.

Authors:  James N Arnold; Lukasz Magiera; Matthew Kraman; Douglas T Fearon
Journal:  Cancer Immunol Res       Date:  2013-11-18       Impact factor: 11.151

Review 5.  The role of NLRs and TLRs in the activation of the inflammasome.

Authors:  Mihai G Netea; Frank L van de Veerdonk; Bart Jan Kullberg; Jos W M Van der Meer; Leo A B Joosten
Journal:  Expert Opin Biol Ther       Date:  2008-12       Impact factor: 4.388

Review 6.  Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword.

Authors:  Marion Dajon; Kristina Iribarren; Isabelle Cremer
Journal:  Immunobiology       Date:  2016-06-14       Impact factor: 3.144

7.  Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.

Authors:  Mara H Sherman; Ruth T Yu; Dannielle D Engle; Ning Ding; Annette R Atkins; Herve Tiriac; Eric A Collisson; Frances Connor; Terry Van Dyke; Serguei Kozlov; Philip Martin; Tiffany W Tseng; David W Dawson; Timothy R Donahue; Atsushi Masamune; Tooru Shimosegawa; Minoti V Apte; Jeremy S Wilson; Beverly Ng; Sue Lynn Lau; Jenny E Gunton; Geoffrey M Wahl; Tony Hunter; Jeffrey A Drebin; Peter J O'Dwyer; Christopher Liddle; David A Tuveson; Michael Downes; Ronald M Evans
Journal:  Cell       Date:  2014-09-25       Impact factor: 41.582

8.  NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma.

Authors:  Donnele Daley; Vishnu R Mani; Navyatha Mohan; Neha Akkad; Gautam S D Balasubramania Pandian; Shivraj Savadkar; Ki Buom Lee; Alejandro Torres-Hernandez; Berk Aykut; Brian Diskin; Wei Wang; Mohammad S Farooq; Arif I Mahmud; Gregor Werba; Eduardo J Morales; Sarah Lall; Benjamin J Wadowski; Amanda G Rubin; Matthew E Berman; Rajkishen Narayanan; Mautin Hundeyin; George Miller
Journal:  J Exp Med       Date:  2017-04-25       Impact factor: 14.307

9.  Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity.

Authors:  Hideki Hara; Kohsuke Tsuchiya; Ikuo Kawamura; Rendong Fang; Eduardo Hernandez-Cuellar; Yanna Shen; Junichiro Mizuguchi; Edina Schweighoffer; Victor Tybulewicz; Masao Mitsuyama
Journal:  Nat Immunol       Date:  2013-11-03       Impact factor: 25.606

Review 10.  The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.

Authors:  Yaojie Fu; Shanshan Liu; Shan Zeng; Hong Shen
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more
  66 in total

Review 1.  Inflammasomes and adaptive immune responses.

Authors:  Katherine A Deets; Russell E Vance
Journal:  Nat Immunol       Date:  2021-02-18       Impact factor: 25.606

Review 2.  NLRP3 inflammasome in cancer and metabolic diseases.

Authors:  Bhesh Raj Sharma; Thirumala-Devi Kanneganti
Journal:  Nat Immunol       Date:  2021-03-11       Impact factor: 25.606

Review 3.  The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.

Authors:  Renee B Chang; Gregory L Beatty
Journal:  J Leukoc Biol       Date:  2020-04-09       Impact factor: 4.962

4.  Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy.

Authors:  Despina Siolas; Emily Vucic; Emma Kurz; Cristina Hajdu; Dafna Bar-Sagi
Journal:  Cell Rep       Date:  2021-08-24       Impact factor: 9.423

5.  Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer.

Authors:  Austin R Dosch; Samara Singh; Xizi Dai; Siddharth Mehra; Iago De Castro Silva; Anna Bianchi; Supriya Srinivasan; Zhen Gao; Yuguang Ban; Xi Chen; Sulagna Banerjee; Nagaraj S Nagathihalli; Jashodeep Datta; Nipun B Merchant
Journal:  Mol Cancer Ther       Date:  2021-09-13       Impact factor: 6.261

6.  Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.

Authors:  Klara Dorman; Miriam Gerckens; Stefan Boeck; Stefan Holdenrieder; Stephan Kruger; Kimberly Krueger; Zsuzsanna Mayer; Alexander Rupp; Danmei Zhang; Lena Weiss; C Benedikt Westphalen; Michael Haas; Michael Guenther; Steffen Ormanns; Frank Klawonn; Jens Werner; Michael von Bergwelt-Baildon; Volker Heinemann
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

Review 7.  Regulation and modulation of antitumor immunity in pancreatic cancer.

Authors:  Joshua Leinwand; George Miller
Journal:  Nat Immunol       Date:  2020-08-17       Impact factor: 25.606

8.  Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer.

Authors:  Vineet K Gupta; Nikita S Sharma; Brittany Durden; Vanessa T Garrido; Kousik Kesh; Dujon Edwards; Dezhen Wang; Ciara Myer; Beatriz Mateo-Victoriano; Sai Sundeep Kollala; Yuguang Ban; Zhen Gao; Sanjoy K Bhattacharya; Ashok Saluja; Pankaj K Singh; Sulagna Banerjee
Journal:  Cancer Res       Date:  2021-05-14       Impact factor: 12.701

9.  Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer.

Authors:  Nina G Steele; Eileen S Carpenter; Samantha B Kemp; Veerin R Sirihorachai; Stephanie The; Lawrence Delrosario; Jenny Lazarus; El-Ad David Amir; Valerie Gunchick; Carlos Espinoza; Samantha Bell; Lindsey Harris; Fatima Lima; Valerie Irizarry-Negron; Daniel Paglia; Justin Macchia; Angel Ka Yan Chu; Heather Schofield; Erik-Jan Wamsteker; Richard Kwon; Allison Schulman; Anoop Prabhu; Ryan Law; Arjun Sondhi; Jessica Yu; Arpan Patel; Katelyn Donahue; Hari Nathan; Clifford Cho; Michelle A Anderson; Vaibhav Sahai; Costas A Lyssiotis; Weiping Zou; Benjamin L Allen; Arvind Rao; Howard C Crawford; Filip Bednar; Timothy L Frankel; Marina Pasca di Magliano
Journal:  Nat Cancer       Date:  2020-10-26

Review 10.  Regulatory B cells in cancer.

Authors:  Daniel Michaud; Colleen R Steward; Bhalchandra Mirlekar; Yuliya Pylayeva-Gupta
Journal:  Immunol Rev       Date:  2020-12-23       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.